The FDA has approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and cardiovascular disease (CVD).
Indications: Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated 1) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 2) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Dosage and administration: Recommended dose is 10 mg once daily, taken in the morning, with or without food. Dose may be increased to 25 mg once daily. Assess renal function before initiating. Do not initiate if eGFR is below 45 mL/min/1.73 m2.
Adverse reactions: The most common adverse reactions associated with Jardiance (5% or greater incidence) were urinary tract infections and female genital mycotic infections.
US Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. FDA web site. December 2, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed December 4, 2016.
This Week's Must Reads
Must Reads in Cardiology
Consumption of SSBs & Risk of Mortality, Circulation; ePub 2019 Mar 18; Malik, et al
Dietary Cholesterol or Egg Consumption & CVD, JAMA; 2019 Mar 19; Zhong, Van Horn, et al
Physical Activity & Incidence of CHD & CVD in Women, JAMA Netw Open; ePub 2019 Mar 15; LaCroix, et al